Preparation, Synergism, and Biocompatibility of in situ Liquid Crystals Loaded with Sinomenine and 5-Fluorouracil for Treatment of Liver Cancer

Jiaojiao Cao,Jie Huang,Shuangying Gui,Xiaoqin Chu

DOI: https://doi.org/10.2147/IJN.S207607

IF: 7.033

2021-06-01

International Journal of Nanomedicine

Abstract:Jiaojiao Cao, 1, * Jie Huang, 1, * Shuangying Gui, 1, 2 Xiaoqin Chu 1, 2 1 Department of Pharmaceutics, Anhui University of Chinese Medicine, Hefei, 230012, People's Republic of China; 2 Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, 230012, People's Republic of China *These authors contributed equally to this work Correspondence: Xiaoqin Chu Master Instructor Tel +86 13856929921 Fax +86 551-68129028 Email Purpose: Transarterial chemoembolization is the preferred treatment for patients with middle and advanced-stage hepatocellular carcinoma (HCC); however, most hepatic artery embolization agents have various disadvantages. The purpose of this study was to evaluate phytantriol-based liquid crystal injections for potential use in treatment of HCC. Methods: Using sinomenine (SN) and 5-fluorouracil (5-FU) as model drugs, three precursor in situ liquid crystal injections based on phytantriol (P1, P2, and P3) were prepared, and their in vitro biocompatibility, anticancer activity, and drug release investigated, to evaluate their feasibility for use in treatment of HCC. The properties of the precursor injections and subsequent cubic liquid crystal gels were observed by visual and polarizing microscopy, in an in vitro gelation experiment. Biocompatibility was evaluated by in vitro hemolysis, histocompatibility, and cytotoxicity assays. Results: Precursor injections were colorless liquids that formed transparent cubic liquid crystal gels on addition of excess water. The three precursor injections all caused slight hemolysis, without agglutination, and were mildly cytotoxic. Histocompatibility experiments showed that P1 had good histocompatibility, while P2 and P3 resulted in strong inflammatory responses, which subsequently resolved spontaneously. In vitro anti-cancer testing showed that SN and 5-FU inhibited HepG2 cells in a time- and concentration-dependent manner and had synergistic effects. Further, in vitro release assays indicated that all three preparations had sustained release effects, with cumulative release of > 80% within 48 h. Conclusion: These results indicate that SN and 5-FU have synergistic inhibitory effects on HepG2 cells, which has not previously been reported. Moreover, we describe a biocompatible precursor injection, useful as a drug carrier for the treatment of liver cancer, which can achieve targeting, sustained release, synergistic chemotherapy, and embolization. These data indicate that precursor injections containing SN and 5-FU have great potential for use in therapy for liver cancer. Keywords: carcinoma, hepatocellular, drug carriers, delayed-action preparations, chemoembolization, therapeutic, SN, 5-FU Liver cancer, 1 , 2 including hepatocellular carcinoma (HCC), cholangiocarcinoma, and other hepatic malignancies, is the sixth most common malignant tumor. Among primary liver cancers, HCC is one of the most common, according to cancer statistics updated in 2019, the estimated number of new HCC case ranks at 14th, while the estimated number of deaths from HCC ranked 5th among cancer-related deaths. Currently, hepatic resection is the main treatment for patients with early-stage HCC, while transarterial chemoembolization (TACE) is preferred for patients with middle- and advanced-stage tumors; 3 however, most traditional hepatic artery embolization agents have disadvantages, including low embolic selectivity, incomplete embolization, and insufficient embolization time, among others. 4 , 5 Phytantriol (PYT) 6 , 7 is an amphiphilic molecule with both hydrophilic hydroxyl groups and hydrophobic carbon chains. When PYT is dispersed in a small amount of water, a very low viscosity magnetic isotropic solution is formed, referred to as a precursor solution, which has the advantages of good mobility and easy injection; however, when PYT is dispersed in sufficient water and other organic solvents, it can form a high viscosity, rigid liquid crystal gel, which is non-toxic and biocompatible. Hence, the PYT precursor solution has the potential for use in TACE, and has been the subject of several reports. 8–11 As the most commonly used uracil anti-metabolite drug, 5-Fluorouracil (5-FU) 12–14 has a broad spectrum of anti-tumor effects. Further, 5-FU is the most widely used drug for treatment of HCC, and has clear therapeutic effects, making it the first choice for treatment -Abstract Truncated-